Cellular release profiling of controlled release dry powder pulmonary formulation

Ong, HX; Traini, D; Bebawy, M; Young, P

Cellular release profiling of controlled release dry powder pulmonary formulation

Ong, HX Traini, D Bebawy, M

Young, P

Permalink

Publisher:: Virginia Commonwealth University
Publication Type:: Conference Proceeding
Citation:: RDD Europe 2011, 2011, pp. 1 - 4
Issue Date:: 2011-01

Closed Access

	Filename	Description	Size
	2011003680OK.pdf	Published version	382.05 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Ong, HX	en_US
dc.contributor.author	Traini, D	en_US
dc.contributor.author	Bebawy, M https://orcid.org/0000-0003-2606-921X	en_US
dc.contributor.author	Young, P	en_US
dc.contributor.editor	Dalby, RN	en_US
dc.contributor.editor	Byron, PR	en_US
dc.contributor.editor	Peart, J	en_US
dc.contributor.editor	Suman, JD	en_US
dc.contributor.editor	Young, PM	en_US
dc.date	2011-05-03	en_US
dc.date.issued	2011-01	en_US
dc.identifier.citation	RDD Europe 2011, 2011, pp. 1 - 4	en_US
dc.identifier.uri	http://hdl.handle.net/10453/31348
dc.description.abstract	Respiratory tract infections (RTI), such as pneumonia, are very common and their treatments represent the largest proportion of the antibacterial market. Rapid pulmonary antibiotic absorption and clearance suggest controlled release (CR) inhaled antibiotic formulations would be beneficial for the treatment of chronic infections. To date, there is no pharmacopoeia methodology for the evaluation of in vitro drug release of respiratory formulations. This could be attributed to the lack of predictability and correlation between available in vitro and in vivo models for pulmonary drugs. Hence, to effectively predict the pharmacokinetics of drugs delivered to the lungs, a model of the airway epithelium is proposed to reflect the transport characteristics in vivo. Ciprofloxacin was chosen as a model drug.	en_US
dc.publisher	Virginia Commonwealth University	en_US
dc.relation.ispartof	RDD Europe 2011	en_US
dc.relation.ispartof	Respiratory Drug Delivery	en_US
dc.title	Cellular release profiling of controlled release dry powder pulmonary formulation	en_US
dc.type	Conference Proceeding
utslib.location	United States	en_US
utslib.location.activity	Germany	en_US
utslib.for	111504 Pharmaceutical Sciences	en_US
dc.location.activity	Germany
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Science
pubs.organisational-group	/University of Technology Sydney/Faculty of Science/School of Mathematical and Physical Sciences
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHT - Health Technologies
utslib.copyright.status	closed_access
pubs.consider-herdc	false	en_US
pubs.finish-date	2011-05-06	en_US
pubs.place-of-publication	United States	en_US
pubs.publication-status	Published	en_US
pubs.start-date	2011-05-03	en_US

Abstract:

Respiratory tract infections (RTI), such as pneumonia, are very common and their treatments represent the largest proportion of the antibacterial market. Rapid pulmonary antibiotic absorption and clearance suggest controlled release (CR) inhaled antibiotic formulations would be beneficial for the treatment of chronic infections. To date, there is no pharmacopoeia methodology for the evaluation of in vitro drug release of respiratory formulations. This could be attributed to the lack of predictability and correlation between available in vitro and in vivo models for pulmonary drugs. Hence, to effectively predict the pharmacokinetics of drugs delivered to the lungs, a model of the airway epithelium is proposed to reflect the transport characteristics in vivo. Ciprofloxacin was chosen as a model drug.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/31348